SOURCE: SECFilings.com

June 21, 2016 09:00 ET

SECFilings.com Examines Innovus Pharmaceuticals' (INNV) Position in Multi-Billion Dollar Female Sexual Dysfunction Market

REDONDO BEACH, CA--(Marketwired - Jun 21, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a look at the underserved Female Sexual Interest Arousal Dysfunction (FSI/AD) market and Innovus Pharmaceuticals' (OTCQB: INNV) clinically proven over-the-counter treatment, Zestra®.

FSI/AD represents a sizable market that is potentially larger than the multi-billion-dollar erectile dysfunction -- or ED -- marketplace. Community studies have shown that FSI/AD affects between 25% and 63% of women with an average prevalence of 43% compared to just 31% for ED's prevalence in men. Despite the prevalence of this condition, there are no FDA approved prescription medications in the market labeled for use in treating FSI/AD. The only existing treatments are used off-label and involve a range of potential adverse side effects, as well as the use of personal lubricants and devices that may or may not be effective.

To view the SECFilings.com article examining Zestra's potential, click on the link below or copy and paste the address in your browser: http://secfilings.com/News.aspx?title=innovus_pharma_(innv)_targets_underserved_multi_billion_dollar_fsi/ad_market&naid=1394

About SECFilings.com

Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

Contact Information